Progressive Pulmonary Fibrosis and Interstitial Lung Abnormalities: <i>AJR</i> Expert Panel Narrative Review.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 38656115.
- Also identified by DOI 10.2214/AJR.24.31125.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Progressive pulmonary fibrosis (PPF) and interstitial lung abnormalities (ILA) are relatively new concepts in interstitial lung disease (ILD) imaging and clinical management. Recognition of signs of PPF and identification and classification of ILA are important tasks during chest high-resolution CT interpretation to optimize management of patients with ILD and those at risk of developing ILD. However, in professional society guidance, the role of imaging surveillance remains unclear for stable patients with ILD, asymptomatic patients with ILA who are at risk of progression, and asymptomatic patients at risk of developing ILD without imaging abnormalities. In this <i>AJR</i> Expert Panel Narrative Review, we summarize the current knowledge regarding PPF and ILA and describe the range of clinical practice with respect to imaging patients with ILD, those with ILA, and those at risk of developing ILD. In addition, we offer suggestions to help guide surveillance imaging in areas with an absence of published guidelines, where such decisions are currently driven primarily by local pulmonologists' preference.
Medical subject headings
- Lung Diseases, Interstitial
- Tomography, X-Ray Computed
- Pulmonary Fibrosis